In the process of cell apoptosis induced by specific reagents, calreticulin (CRT) in endoplasmic reticulum is transferred and coated onto the cell membrane. As a sort of specific ligand, the CRT on the surface of apoptotic cells could mediate recognition and clearance of apoptotic cells by phagocytes. In this research we discovered that mitoxantrone could induce apoptosis of mouse melonoma B16-F1 tumor cells, accompanied by the membrane translocation and coating of CRT. When mitoxantrone-treated B16-F1 cells were used as antigen to inoculate mice, the mice acquired an ability to suppress proliferation of homologous tumor cells. Splenocytes from these mice showed an increased cytolytic effect on homologous B16-F1 cells but no such effect on non-homologous H22 tumor cells. All these results suggested that mitoxantrone-treated apoptotic B16-F1 cells could be used as a sort of cell vaccine to initiate effective anti-tumor immunoresponse in mice. Cellular & Molecular Immunology. 2009;6(6):469-475.
Introduction
One important factor of tumor generation is that mutated tumor cells escape from immunological surveillance by lowering the expression of membrane marker molecules which play essential roles in the process of cell recognition and phagocytosis (1) (2) (3) (4) . It has been expected to achieve an effective tumor prevention and treatment by restoring or stimulating body's immune response against the cancers.
Calreticulin (CRT) is a highly conservative Ca 2+ -binding protein which is ubiquitous in mammalian and mostly presents at the endoplasmic reticulum (ER) lumen. CRT has multiple biological functions which are relevant to its subcellular localization, including chaperone functions, lectin binding, activation of store-operated Ca 2+ influx, regulation of cell adhesion and removal of apoptotic cells, etc (6) (7) (8) (9) (10) (11) . Recently, it has been proved that CRT in the membrane of apoptotic cells was the key molecule involved in the recognition and clearance of apoptotic cells (12) (13) (14) (15) (16) . In 2006, Obeid M and his colleagues discovered that treating CT-26 cells (mouse colon carcinoma cells) with anthracycline, one class of antitumor drugs used in the clinic, resulted in translocation of CRT from ER to cell surface along with the cell apoptosis. When these CRT-coated apoptotic CT-26 cells were used as antigen to immune animals, the specific anti-tumor immune response was elicited in tumor bearing mice. The possible mechanism was that, as a specific marker, the CRT on the surface of apoptotic cells was recognized by dendritic cells or other antigen presenting cells (APCs) that lead to the collective phagocytosis of apoptotic cells. Within the APCs, tumor associated antigens (TAA) or tumor special antigens (TSA) were subsequently processed and presented to CD4 + and CD8 + T lymphocytes, and finally specific anti-tumor immune response was elicited in the experimental animals (18, 19) . These researches suggest a potential importance of CRT in tumor immunotherapy.
In order to further prove the universal value of CRT in anti-tumor immunity, in this study, the effect of specific anti-tumor immune response mediated by mitoxantronetreated B16-F1 cells was evaluated. Results demonstrated that mitoxantrone, a member of the anthracycline family, could also induce apoptosis and CRT membrane translocation in mouse melanoma B16-F1 cells. And when the mitoxantrone-treated cells were used as cell-antigen to immune mice, the specific immune response against homologous tumor cells was observed.
Materials and Methods
Experimental animals and cell lines BALB/c mice (7-8 weeks old) were purchased from Hubei Experimental Animal Center (No. 0001839). All the animals were housed under specific pathogen free conditions. The mouse melanoma cell line B16-F1 and hepatocellular carcinoma cell line H22 were maintained in our laboratory. 
Drugs and chemicals

Cell culture
Cells were cultured in flasks with RPMI-1640 medium supplemented with 10% (v/v) calf serum, 100 g/ml streptomycin and 100 units/ml penicillin in a humidified 5% CO 2 and 95% air incubator at 37°C.
Cellular proliferation assay
B16-F1 cells were seeded into 96-well culture plates (4,000 cells/well in 50 L standard RPMI-1640 medium) in triplicate. Twenty four hours later, the cells were treated with mitoxantrone at different concentrations in 50 L medium. The cells treated with equal amount of normal medium instead of drugs were served as control. After drug exposure for 24 h or 48 h, the medium in each well was removed and 200 l MTT solution (0.25 g/L in RPMI-1640 medium) was added. After 4 h incubation at 37°C, the medium was removed and 200 l dimethyl sulfoxide was added into each well. After 10 min incubation at room temperature, absorbance (A) at 570 nm was recorded. The cell survival rate was calculated as follows: Cell survival rate = A drug / A control × 100% Detection of apoptosis by DNA fragmentation analysis B16-F1 cells were cultured in RPMI-1640 medium containing mitoxantrone (1 g/ml) for 0 h, 4 h, 12 h and 24 h. Harvested cells were then lysed in 0.3 ml cell lysis buffer (50 mM Tris-HCL, 20 mM EDTA, 0.5% Triton X-100, pH 8.0) for 20 min, on ice. Nuclei was removed from cell lysate by centrifuge at 12000 r/min for 10 min and then the supernatant was extracted with phenol/chloroform. The DNA fragments in extracted supernatant were precipitated with 2 volumes of 100% ethanol and 1/10 volume of 3 mol/L sodium acetate (pH 5.2), and the pellets were resuspended in 0.1 × SSC buffer. After treatment with DNase-free RNase A (50 mg/ml) for 30 min at 37°C to remove RNA, NaCl was added into the solution for a final concentration of 1 mol/L and the solution was extracted again with phenol/chloroform and DNA was precipitated by ethanol. The pellets were suspended in 30 L ddH 2 O and loaded to a 2% (w/v) agarose gel for electrophoresis.
Western blot analysis B16-F1 cells were cultured in RPMI-1640 medium containing mitoxantrone (1 g/ml) for 12 h and harvested. Cells were then treated with cell lysis buffer (as described above) for 20 min on ice. Nuclei and cytoplasm were separated from each other by centrifuge at 1000 r/min for 5 min. A total of 5 g of nuclei or cytoplasm proteins from each sample was denatured by boiling, loaded onto a 10% (w/v) SDS-PAGE and transferred onto PVDF membranes. After blocking with 5% (w/v) non-fat milk, the blots were probed with specific primary Abs and visualized with the HRP-conjugated secondary Abs and ECL detection system. -actin was used as a loading control in this sutdy.
Quantitative real-time PCR
The CRT mRNA levels in B16-F1 cells before and after mitoxantrone (1 g/ml) treatment were detected by quantitative realtime PCR and expressed relatively to the expression of-actin. The first-strand cDNA was synthesized from total RNA of B16-F1 cells by reverse transcription. Real-time PCR was performed with SYBR PrimeScript 
Immunofluorescence detection of calreticulin in B16-F1
Immunofluorescence was used to determine the subcellular localization of CRT. B16-F1 cells were seeded into 12-well culture plates (2 × 10 4 /well in 1 ml standard RPMI-1640 medium). Twenty four hours later, the cells were treated with mitoxantrone (1 g/ml) in 1 ml medium for 12 h. B16-F1 cells treated with equal amount of normal medium instead of Volume 6 Number 6 December 2009 drugs were served as the control group. After 12 h, the medium was discarded and the cells were washed with PBS and treated with 4% (w/v) paraformaldehyde for fixation. The cells were then washed with PBS, incubated with 10% (v/v) goat serum for blocking background and reacted with anti-CRT pAbs over night at 4°C. The cells were then washed with PBS, incubated with Rhodamine-123 labeled anti-rabbit IgG for 45 min at 37°C. Finally, the cells were stained with 300 nmol/L DAPI for nuclei, washed with PBS, enclosed in 50% glycerol (diluted in 0.01 mol/L PBS, pH 8.0) and examined by fluorescence/phase contrast microscopy (TE2000S, Nikon, Japan).
Animal experiments BALB/c mice (26 male, 27 female, n = 53) were randomly divided into 3 groups: 1) PBS group (blank control, n = 14), 2) B16 group (tumor control, n = 20) and 3）B16-NVI group (immune-inoculated group, n = 19). Apoptotic B16-F1 cells induced by mitoxantrone (1 g/ml) for 12 h were subcutaneouly inoculated into the back of each mouse in B16-NVI group, PBS instead of mitoxantrone-treated B16-F1 cells was used to inoculate other two control groups of mice at the same time. The second-time animal immunization was performed 10 days after the first-time immunization. Ten days after the second immunization, living B16-F1 cells (5.0 × 10 5 cells in 100 L PBS for each) were subcutaneouly injected into the back of each mouse in B16 group and B16-NVI group. The mice in PBS group were subcutaneouly injected PBS as the tumor-free group. Then mice were monitored once every two days after injection. Appearance of black-blue spots in inoculated area was regarded as tumor begins to generate.
LDH release assay
The splenocytes were obtained from the experimental mice and isolated with lymphocyte separation medium and then used as effector cells in the LDH release assay. The splenocytes were seeded into 96-well culture plates (1 × 10 6 cells/well) in 100 l RPMI-1640 medium without phenolsulphonphthalein in triplicate. B16-F1 cells, used as target cells, were then seeded into the wells that contained splenocytes in 100 l in RPMI-1640 medium in three different effector/target cells ratio (1 : 25, 1 : 50, 1 : 100). In the natural release group, target cells were replaced by equal volume of medium. In the maximum release group, effector cells were replaced by equal volume of 0.1% NP-40. After incubation for 3 h, the cell culture plates were centrifugated at 2000 r/min for 5 min. Cell medium was then transfered to fresh culture plates (100 l/well) and equal volume of LDH substrate reaction buffer (80 g/ml phenazine methosulfate, 320 g/ml nitrotetrazoliumbluechlorid, 800 g/ml codehydrogenase I, sodium lactate 40 mmol/L) was added. After 10-min incubation at 37°C in dark, enzyme reaction was stopped by citric acid (30 L/well) and then absorbance (A) at 450 nm was recorded at room temperature. The cell killing rate was calculated as follow: Rate of cytolysis = (A effector -A natural release ) / A maximum release × 100%
Detection of IFN- in mouse serum by ELISA Blood was collected from experimental mice and incubated at 37°C for 30 min to obtain serum IFN- concentration in mouse serum was determined by ELISA assay according the manufacturer's protocol.
Statistical analysis
All data were presented as mean ± standard deviation (SD). Statistical analysis between groups was assessed by Student's two-tailed t-test. Data for animal tumor model experiment were evaluated by Fisher's exact probabilities in 2 × 2 table, p-values less than 0.05 were regarded as statistically significant.
Results
Mitoxantrone inhibited growth of B16-F1 cells by inducing apoptosis
It has been proved that anti-tumor chemical mitoxantrone could induce apoptosis of mouse colon carcinoma cells along with the translocation of CRT from ER to cell surface. In order to determine whether mitoxantrone was also toxic to B16-F1 cells, MTT cellular survival assay and DNA fragmentation assay were performed in this study. As shown in the Figure 1A , mitoxantrone exhibited significant inhibition on the growth of B16-F1 cells in a dose-and time-dependent manner. DNA fragmenttation assay showed that after treatment with mitoxantrone (1 g/ml) for different times (4 h, 12 h and 24 h), typical DNA ladders for apoptosis were observed in the cell cytosol and the intensity of DNA ladder was increased with the extension of time ( Figure 1B) , suggesting that mitoxantrone could effectively induce apoptosis of B16-F1 cells.
Effects of mitoxantrone on CRT expression and its subcellular localization in B16-F1 cells
To validate whether mitoxantrone treatment could affect CRT expression and its subcellular localization in B16-F1 cells along with the apoptosis, the Western blot assay was used to assay CRT protein content in whole cell lysate, cytosol and nuclei. QT-RT-PCR was performed to determine CRT mRNA level, and immunofluorescence assay was used to observe the subcellular localization of CRT in B16-F1 cells. Western blot assay showed that mitoxantrone treatment for 12 h did not change total cellular CRT level, but resulted in a decreased CRT content in nuclei and an increased CRT content in the cytoplasm (Figure 2A ). This observation was also supported by QT-RT-PCR assay for CRT mRNA. As shown in Figure 2B , no significant differences on the mRNA levels of CRT were determined between mitoxantrone-treated and control B16-F1 cells. The subcellular localization of CRT in B16-F1 cells was also evaluated by immunofluorescence detection. Results showed that mitoxantrone treatment induced an obvious membrane translocation of CRT and, very importantly, the CRT coated on the membrane was found to crow together on the cell surface ( Figure 2C ). In B16-F1 control cells, CRT mainly distributed in cytoplasm as described by Ostwald and his colleagues (5) . were used as effectors and B16-F1 cells were used as targets. In a parallel assay, H22 cells, as a sort of nonhomologous tumor cells, were used as target cells to prove the specificity of cytolysis. The results showed that, comparied with the splenocytes from the mice in PBS group and B16 group, the splenocytes from immune-inoculated mice (B16-NVI group) exhibited a significant higher cytolytic efficiency against B16-F1 cells ( Figure 4A ). In the parallel experiment, the splenocytes from all three different groups of mice exhibited a similar cytolytic efficiency against H22 cells ( Figure 4B ). These results suggested that the immune response induced by mitoxantrone-treated B16-F1 cells was specifically against homogeneous tumor cells.
IFN- is a cytokine that is critical for innate and adaptive immunity for tumor control. It is produced predominantly by natural killer (NK) and natural killer T (NKT) cells as part of the innate immune response, and by CD4 and CD8 cytotoxic T lymphocyte (CTL) effector T cells once antigen-specific immunity develops. To validate whether immunizing mice with mitoxantrone-treated B16-F1 cells can increase release of IFN- by immune cells, the interferon- level in mouse serum was determined by ELISA method. Data showed that the serum interferon- levers in the mice of B16-NVI group were obviously higher than in the mice of other two groups ( Figure 4C ).
Discussion
Mitoxantrone, as a membrane of anthracyclines family, is an anti-tumor drug widely used in the clinic. The studies have pointed out that mitoxantrone could induce apoptosis of CT-26 colon cancer cells along with the CRT membrane translocation and aggregation on the cell surface. When these CRT-coated apoptotic cells were used as the antigen to inoculate mice, a specific anti-tumor effect against homogeneous tumor cells were observed in the experimental animals (20) (21) (22) , suggesting a potential importance of membrane CRT in mediating anti-tumor immune response. In this research, we discovered that mitoxantrone was also toxic to mouse B16-F1 melanoma cell line. Treatment with mitoxantrone (1 g/ml) could induce apoptosis of B16-F1 and, in the same time, CRT was transferred to and aggregated on the cell surface. Subsequently, we immunized BALB/c mice with mitoxantrone-treated B16-F1 cells as antigen and rechallenged the animals with live B16-F1 cells 20 days later. The results showed that the immunization by mitoxantronetreated B16-F1 cells induced a protective effect against attack of live B16-F1 cancer cells in the mice. Ten days after rechallenge by live B16-F1 cells, the percent of tumorbearing mice in the immune-inoculating group (15%) was much lower than that in non-inoculating group (85%). The data from LDH release assay showed that the splenocytes from immune-inoculated mice exhibited a more potent cytotoxic effect on B16-F1 cells than those from the control mice, but no such difference was observed when the non-homologous H22 cancer cells were used as the target cells, suggesting a specific immune activation against homologous cell-antigen. ELISA assay also demonstrated that serum concentrations of interferon- were obviously increased only in immune-inoculated mice. Interferon- was an essential immune effector released by activated immunocytes, so that the serum concentration of interferon- could indirectly represent the active extent of immune system in vivo.
The possible mechanism underlying the CRT-mediated anti-tumor immunity is that CRT coating induced by mitoxantrone-treatment gives B16-F1 cells a stronger immunogenicity. When these CRT-coated cells were inoculated into the animals, the cells can be recognized by and phagocytosed into the immunocytes in which tumorspecific antigens are processed and presented, which finally resulted in a specific anti-tumor immunity against the homologous tumor cells.
On the whole, all our data indicate a potential role of membrane CRT in mediating anti-tumor immunity. This study provides a new idea and approach for tumor immune prevention and treatment. But the tumor-antigens and antigen-presenting immune cells that involve in the immune process still need to be identified in the further experiments.
